OIG Supplemental Advisory Bulletin on Patient Assistance Programs Leaves Open Questions for High-Cost Breakthrough Drugs in Medicare Part D

Published date30 May 2014
Law FirmEpstein Becker & Green
AuthorAnjali Downs,Philo Hall,Mark Hamelburg,Thomas Hutchinson,Deepa Selvam
Subject MatterHealthcare,HHS,Medicare,Medicare Part D,OIG,Patient Assistance Programs,Pharmaceutical Industry,Prescription Drugs

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT